About
NaDeNo develops a nanoparticle-based drug delivery platform that enables encapsulation and local delivery of hard-to-deliver molecules, with a lead candidate PACAB-002 targeting peritoneal micrometastases in high-grade serous ovarian cancer planned to enter Phase I trials in early 2027.
Explore NaDeNo's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.